We are live on ! Find out more
BIS icon

ProShares UltraShort NASDAQ Biotechnology
BIS

7 hedge funds and large institutions have $1.88M invested in ProShares UltraShort NASDAQ Biotechnology in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

173% more capital invested

Capital invested by funds: $691K → $1.88M (+$1.19M)

40% more funds holding

Funds holding: 5 → 7 (+2)

9.71% more ownership

Funds ownership: 9.83% → 19.54% (+9.7%)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

Holders
7
Holders Change
+2
Holders Change %
+40%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
OMC
Old Mission Capital
Illinois
+$484K
2
IMC Chicago
IMC Chicago
Illinois
+$477K
3
Citadel Advisors
Citadel Advisors
Florida
+$267K
4
UBS Group
UBS Group
Switzerland
+$12.4K

Top Sellers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
-$118K
2
Morgan Stanley
Morgan Stanley
New York
-$5.05K

BIS Hedge Fund Activity: Q1 2022 in Review

7 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q1 2022, worth a combined $1.88M — up 173% from $691K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new BIS positions and 0 closed out — a net gain of 2 holders — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Old Mission Capital, adding an estimated $484K. The largest seller was Tower Research Capital (TRC), cutting an estimated $118K.

  • 7 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q1 2022, up from 5 in Q4 2021.
  • Funds reported $1.88M of ProShares UltraShort NASDAQ Biotechnology stock for Q1 2022, up 173% quarter-over-quarter.
  • 2 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q1 2022 and 0 closed out, a net change of +2 holders.
  • The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q1 2022 was Old Mission Capital, an estimated $484K added.
  • The largest ProShares UltraShort NASDAQ Biotechnology seller in Q1 2022 was Tower Research Capital (TRC), an estimated $118K sold.

Based on aggregated 13F filings for Q1 2022.